Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 265Leukemia, Lymphocytic, Chronic, B-Cell 66Lymphoma, Large B-Cell, Diffuse 60Neoplasms, Plasma Cell 50Lymphoma, Follicular 45Lymphoma, Mantle-Cell 42Lymphoma 41Recurrence 38Lymphoma, B-Cell, Marginal Zone 31Leukemia 30Leukemia, Myeloid, Acute 27Lymphoma, B-Cell 19Lymphoma, Non-Hodgkin 17Myelodysplastic Syndromes 16Waldenstrom Macroglobulinemia 15Smoldering Multiple Myeloma 13Hodgkin Disease 13Lymphoma, T-Cell, Peripheral 12Neoplasms 11Lymphoma, T-Cell 9Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Immunoglobulin Light-chain Amyloidosis 8Burkitt Lymphoma 8Sezary Syndrome 7Neoplasm, Residual 7Mycosis Fungoides 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Plasma Cell 6

Interventions

Dexamethasone 5Lenalidomide 3pomalidomide 2isatuximab 2daratumumab 2nirogacestat 1Ranitidine 1Diphenhydramine 1Cyclophosphamide 1Bortezomib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Blood Protein Disorders × Lenalidomide × Clear all
NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Hellenic Society of Hematology

Phase 1/2 Unknown
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡